Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease Research Summary
This study investigated whether low-dose rivaroxaban reduces major adverse cardiovascular events compared with placebo in adults with advanced chronic kidney disease (CKD) stage 4 or 5, including those receiving dialysis.
Original Source
Read the full article at Jamanetwork →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.